Trond Ulven

Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets

The deorphanization of the free fatty acid (FFA) receptors FFA1 (GPR40), FFA2 (GPR43), FFA3 (GPR41), GPR84, and GPR120 has made clear that the body is capable of recognizing and responding directly to nonesterified fatty acid of virtually any chain length. Colonic fermentation of dietary fiber produces high concentrations of the short-chain fatty acids (SCFAs) acetate, propionate and butyrate, a process which is important to health. The phylogenetically related 7-transmembrane (7TM) receptors free fatty acid receptor 2 (FFA2) and FFA3 are activated by these SCFAs, and several lines of evidence indicate that FFA2 and FFA3 mediate beneficial effects associated with a fiber-rich diet, and that they may be of interest as targets for treatment of inflammatory and metabolic diseases. FFA2 is highly expressed on immune cells, in particular neutrophils, and several studies suggest that the receptor plays a role in diseases involving a dysfunctional neutrophil response, such as inflammatory bowel disease (IBD). Both FFA2 and FFA3 have been implicated in metabolic diseases such as type 2 diabetes and in regulation of appetite. More research is however required to clarify the potential of the receptors as drug targets and establish if activation or inhibition would be the preferred mode of action. The availability of potent and selective receptor modulators is a prerequisite for these studies. The few modulators of FFA2 or FFA3 that have been published hitherto in the peer-reviewed literature in general have properties that make them less than ideal as such tools, but published patent applications indicate that better tool compounds might soon become available which should enable studies critical to validate the receptors as new drug targets.

Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation

BackgroundMast cell-derived prostaglandin D2 (PGD2), may contribute to eosinophilic inflammation and mucus production in allergic asthma. Chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2), a high affinity receptor for prostaglandin D2, mediates trafficking of TH2-cells, mast cells, and eosinophils to inflammatory sites, and has recently attracted interest as target for treatment of allergic airway diseases. The present study involving mice explores the specificity of CRTH2 antagonism of TM30089, which is structurally closely related to the dual TP/CRTH2 antagonist ramatroban, and compares the ability of ramatroban and TM30089 to inhibit asthma-like pathology.MethodsAffinity for and antagonistic potency of TM30089 on many mouse receptors including thromboxane A2 receptor mTP, CRTH2 receptor, and selected anaphylatoxin and chemokines receptors were determined in recombinant expression systems in vitro. In vivo effects of TM30089 and ramatroban on tissue eosinophilia and mucus cell histopathology were examined in a mouse asthma model.ResultsTM30089, displayed high selectivity for and antagonistic potency on mouse CRTH2 but lacked affinity to TP and many other receptors including the related anaphylatoxin C3a and C5a receptors, selected chemokine receptors and the cyclooxygenase isoforms 1 and 2 which are all recognized players in allergic diseases. Furthermore, TM30089 and ramatroban, the latter used as a reference herein, similarly inhibited asthma pathology in vivo by reducing peribronchial eosinophilia and mucus cell hyperplasia.ConclusionThis is the first report to demonstrate anti-allergic efficacy in vivo of a highly selective small molecule CRTH2 antagonist. Our data suggest that CRTH2 antagonism alone is effective in mouse allergic airway inflammation even to the extent that this mechanism can explain the efficacy of ramatroban.

Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II Diabetes

A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA(1)) has been discovered and explored. The preferred compound 20 (TUG-424, EC(50) = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA(1) in metabolic diseases such as diabetes or obesity.

Discovery of a Potent and Selective GPR120 Agonist

GPR120 is a receptor of unsaturated long-chain fatty acids reported to mediate GLP-1 secretion, insulin sensitization, anti-inflammatory, and anti-obesity effects and is therefore emerging as a new potential target for treatment of type 2 diabetes and metabolic diseases. Further investigation is however hindered by the lack of suitable receptor modulators. Screening of FFA1 ligands provided a lead with moderate activity on GPR120 and moderate selectivity over FFA1. Optimization led to the discovery of the first potent and selective GPR120 agonist.

The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism

TUG-891 [3-(4-((4-fluoro-4′-methyl-[1,1′-biphenyl]-2-yl)methoxy)phenyl)propanoic acid] was recently described as a potent and selective agonist for the long chain free fatty acid (LCFA) receptor 4 (FFA4; previously G protein–coupled receptor 120, or GPR120). Herein, we have used TUG-891 to further define the function of FFA4 and used this compound in proof of principle studies to indicate the therapeutic potential of this receptor. TUG-891 displayed similar signaling properties to the LCFA α-linolenic acid at human FFA4 across various assay end points, including stimulation of Ca2+ mobilization, β-arrestin-1 and β-arrestin-2 recruitment, and extracellular signal-regulated kinase phosphorylation. Activation of human FFA4 by TUG-891 also resulted in rapid phosphorylation and internalization of the receptor. While these latter events were associated with desensitization of the FFA4 signaling response, removal of TUG-891 allowed both rapid recycling of FFA4 back to the cell surface and resensitization of the FFA4 Ca2+ signaling response. TUG-891 was also a potent agonist of mouse FFA4, but it showed only limited selectivity over mouse FFA1, complicating its use in vivo in this species. Pharmacologic dissection of responses to TUG-891 in model murine cell systems indicated that activation of FFA4 was able to mimic many potentially beneficial therapeutic properties previously reported for LCFAs, including stimulating glucagon-like peptide-1 secretion from enteroendocrine cells, enhancing glucose uptake in 3T3-L1 adipocytes, and inhibiting release of proinflammatory mediators from RAW264.7 macrophages, which suggests promise for FFA4 as a therapeutic target for type 2 diabetes and obesity. Together, these results demonstrate both potential but also significant challenges that still need to be overcome to therapeutically target FFA4.

The Oxygen‐Mediated Synthesis of 1,3‐Butadiynes in Continuous Flow: Using Teflon AF‐2400 to Effect Gas/Liquid Contact

In recent years, as the ecological impact of technology and industrial processes has become clearer, there has been a growing demand for more environmentally benign and sustainable chemical processes. One noteworthy example of this ongoing trend has been the development of oxidative processes that use molecular oxygen as the reagent, either directly or in conjunction with catalysis. As well as for typical functional group oxidations, molecular oxygen is seeing significant and increasing use in several synthetically important carbon carbon bond forming reactions. Of these, the Glaser–Hay oxidative acetylene coupling reaction to form 1,3-butadiynes is an important example. The intense research interest in this reaction is largely due the importance of the conjugated diyne and polyyne products, which have very interesting electronic, optical, and material properties. Being completely ecologically compatible, the use of molecular oxygen is clearly advantageous when compared with other common metal-based oxidants (e.g. , chromium(VI) reagents, permanganate). The latter have significant toxicity and their use necessitates expensive and energy-intensive clean-up procedures. Importantly, the gaseous nature of oxygen facilitates its separation from products, thereby permitting the use of excess oxidant in order to drive reactions to completion. However, this also leads to severe complications from a process standpoint, in that gas/liquid phase-transfer phenomena have to be considered. Whilst several practical methods exist to increase the dissolution rate of oxygen (and other gases) into solution (e.g. , sparging, agitation, vortex mixing), the accurate control of these processes is by no means trivial. In addition, owing to changes in physical parameters such as surface-to-volume ratios, the scale-up of batch chemical processes that involve a gas/liquid interface is often much more complex than simply using a bigger reaction vessel. An obvious further consideration with gaseous reagents such as oxygen is that the high pressures often required to obtain adequate solution concentrations (according to Henry’s law) call for specialized and expensive containment vessels, and raise safety concerns. Flow chemistry (and related continuous processing techniques) has emerged recently as an alternative paradigm of synthesis chemistry that offers solutions to some of the problems associated with batch processing. In particular, as the physical parameters of the processing zones are fixed (and small), the scale-up of reaction processes is greatly simplified and can be achieved either by increasing the running-time of a reaction, or by parallelization of the reaction through multiple identical paths (“scale-out”). This is especially advantageous for processes that involve hazardous intermediates or conditions (e.g. , high pressures or temperatures), as the total hazard present at any one time is kept to a minimum. Additionally, mixing processes (including interfacial transfer) are often enhanced due to the small physical scale (and, hence, increased surface-to-volume ratio) of the reaction zones. Notwithstanding the potential benefits of conducting gas/ liquid chemistry in flow, development in this area has been relatively slow, perhaps due to the difficulty of achieving accurate and reliable control of the interfacial processes. Until recently, approaches to solve these problems have focused on “mechanical mixing” of the two phases in order to achieve greater interfacial surface areas, and this has resulted in some interesting engineering developments. However, the relationship between the morphology of the interface (hence, reaction conversion) and flow rate is often non-linear, and this can cause severe difficulty with reaction optimization. Seeking a more generally applicable, consistent, and wellcontrolled method of gas/liquid contact, we conceived the use of semi-permeable membranes to generate homogeneous gas solutions. We have shown that Teflon AF-2400 (a co-polymer of tetrafluoroethene and a perfluorodimethyldioxolane) is very well suited to this purpose as it is extremely permeable to a wide range of gases but practically impermeable to liquids, and exhibits much of the chemical resistance associated with polytetrafluoroethylene (PTFE). By using a simple “jar” reactor we demonstrated the use of this material for the ozonolysis of alkenes, and more recently we have developed a “tube-intube” reactor that has been used to effect carboxylations and hydrogenations at elevated pressures. Herein, we present our initial findings on the use of oxygen in such a reactor to effect Glaser–Hay couplings of terminal alkynes in continuous flow. The permeability of the AF-2400 tubing to molecular oxygen can be demonstrated by using a visual indicator that changes color in the presence of the gas. Shown in Figure 1 are photographs of a coil of the AF-2400 tubing in a sealed glass vessel, the contents of which were continuously flushed with either air, oxygen, or argon (all at [a] T. P. Petersen, Dr. A. Polyzos , Dr. M. O’Brien, Dr. I. R. Baxendale, Prof. S. V. Ley Whiffen Laboratory, Department of Chemistry University of Cambridge Lensfield Road, Cambridge (UK) E-mail : svl1000@cam.ac.uk [b] T. P. Petersen, Dr. T. Ulven Department of Physics and Chemistry University of Southern Denmark, Odense (Denmark) [c] T. P. Petersen Discovery Chemistry and DMPK H. Lundbeck A/S, Valby (Denmark) [d] Dr. A. Polyzos CSIRO, Materials Science and Engineering Bayview Avenue, Clayton South, VIC 3169 (Australia) Sp eial Isu e: lo w C h em itry

Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists IDENTIFICATION OF THE STRUCTURAL AND CHEMICAL REQUIREMENTS FOR SELECTIVE ACTIVATION OF FFA2 VERSUS FFA3

Free fatty acid receptor 2 (FFA2; GPR43) is a G protein-coupled seven-transmembrane receptor for short-chain fatty acids (SCFAs) that is implicated in inflammatory and metabolic disorders. The SCFA propionate has close to optimal ligand efficiency for FFA2 and can hence be considered as highly potent given its size. Propionate, however, does not discriminate between FFA2 and the closely related receptor FFA3 (GPR41). To identify FFA2-selective ligands and understand the molecular basis for FFA2 selectivity, a targeted library of small carboxylic acids was examined using holistic, label-free dynamic mass redistribution technology for primary screening and the receptor-proximal G protein [35S]guanosine 5′-(3-O-thio)triphosphate activation, inositol phosphate, and cAMP accumulation assays for hit confirmation. Structure-activity relationship analysis allowed formulation of a general rule to predict selectivity for small carboxylic acids at the orthosteric binding site where ligands with substituted sp3-hybridized α-carbons preferentially activate FFA3, whereas ligands with sp2- or sp-hybridized α-carbons prefer FFA2. The orthosteric binding mode was verified by site-directed mutagenesis: replacement of orthosteric site arginine residues by alanine in FFA2 prevented ligand binding, and molecular modeling predicted the detailed mode of binding. Based on this, selective mutation of three residues to their non-conserved counterparts in FFA3 was sufficient to transfer FFA3 selectivity to FFA2. Thus, selective activation of FFA2 via the orthosteric site is achievable with rather small ligands, a finding with significant implications for the rational design of therapeutic compounds selectively targeting the SCFA receptors.

The Role of the Prostaglandin D2 Receptor, DP, in Eosinophil Trafficking

Prostaglandin (PG) D2 is a major mast cell product that acts via two receptors, the D-type prostanoid (DP) and the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) receptors. Whereas CRTH2 mediates the chemotaxis of eosinophils, basophils, and Th2 lymphocytes, the role of DP has remained unclear. We report in this study that, in addition to CRTH2, the DP receptor plays an important role in eosinophil trafficking. First, we investigated the release of eosinophils from bone marrow using the in situ perfused guinea pig hind limb preparation. PGD2 induced the rapid release of eosinophils from bone marrow and this effect was inhibited by either the DP receptor antagonist BWA868c or the CRTH2 receptor antagonist ramatroban. In contrast, BWA868c did not inhibit the release of bone marrow eosinophils when this was induced by the CRTH2-selective agonist 13,14-dihydro-15-keto-PGD2. In additional experiments, we isolated bone marrow eosinophils from the femoral cavity and found that these cells migrated toward PGD2. We also observed that BWA868c inhibited this response to a similar extent as ramatroban. Finally, using immunohistochemistry we could demonstrate that eosinophils in human bone marrow specimens expressed DP and CRTH2 receptors at similar levels. Eosinophils isolated from human peripheral blood likewise expressed DP receptor protein but at lower levels than CRTH2. In agreement with this, the chemotaxis of human peripheral blood eosinophils was inhibited both by BWA868c and ramatroban. These findings suggest that DP receptors comediate with CRTH2 the mobilization of eosinophils from bone marrow and their chemotaxis, which might provide the rationale for DP antagonists in the treatment of allergic disease.

Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation.

The involvement of prostaglandin D(2) (PGD(2)) in inflammatory diseases like allergy and asthma is well established, thus blocking the effect of this mediator represents a novel therapeutic approach for the treatment of such diseases. PGD(2) is now known to act through two seven-transmembrane (7TM) receptors, DP (DP(1)) and CRTH2 (DP(2)), which are also activated by several endogenous metabolites from the arachidonic acid cascade, making the regulatory system highly complex. There has recently been a considerable effort aimed at developing antagonists of the PGD(2) receptors for treatment of inflammatory conditions like asthma and rhinitis. Several potent DP antagonists are now known, and one of these is currently in clinical trials for treatment of asthma. CRTH2 has received much attention since its identification as the second high affinity PGD(2) receptor in 2001, and a number of potent and selective antagonists have recently become available. This review will briefly discuss the biological background and validation of DP and CRTH2 as targets for antiinflammatory drugs, and then highlight developments in medicinal chemistry which have appeared in journals and patent applications in the last few years, and which have brought us closer to therapeutic applications of PGD(2) receptor antagonists in various indications.

Extracellular Ionic Locks Determine Variation in Constitutive Activity and Ligand Potency between Species Orthologs of the Free Fatty Acid Receptors FFA2 and FFA3

Background: Differences in ligand potency and selectivity are observed between human and mouse FFA2 and FFA3 orthologs. Results: Potency differences result from differential constitutive activity between species. Conclusion: An “ionic lock” between extracellular loop 2 and the ligand binding pocket regulates constitutive activity. Significance: Understanding species differences in FFA2 and FFA3 function is critical to future studies with these receptors. Free fatty acid receptors 2 and 3 (FFA2 and FFA3) are G protein-coupled receptors for short chain free fatty acids (SCFAs). They respond to the same set of endogenous ligands but with distinct rank-order of potency such that acetate (C2) has been described as FFA2-selective, whereas propionate (C3) is non-selective. Although C2 was confirmed to be selective for human FFA2 over FFA3, this ligand was not selective between the mouse orthologs. Moreover, although C3 was indeed not selective between the human orthologs, it displayed clear selectivity for mouse FFA3 over mouse FFA2. This altered selectivity to C2 and C3 resulted from broad differences in SCFAs potency at the mouse orthologs. In studies to define the molecular basis for these observations, marked variation in ligand-independent constitutive activity was identified using a [35S]GTPγS assay. The orthologs with higher potency for the SCFAs, human FFA2 and mouse FFA3, displayed high constitutive activity in this assay, whereas the orthologs with lower potency for the agonist ligands, mouse FFA2 and human FFA3, did not. Sequence alignments of the second extracellular loop identified single negatively charged residues in FFA2 and FFA3 not conserved between species and predicted to form ionic lock interactions with arginine residues within the FFA2 or FFA3 agonist binding pocket to regulate constitutive activity and SCFA potency. Reciprocal mutation of these residues between species orthologs resulted in the induction (or repression) of constitutive activity and in most cases also yielded corresponding changes in SCFA potency.